Researchers Develop Web-based App to Predict Glioma Mutations

A new web-based program developed by researchers at University of Kentucky Markey Cancer Center provides a simple, free way for health-care providers to determine which brain tumor cases require testing for a genetic mutation. In some specific cases of gliomas, patients have a mutation in a gene, known as an IDH1 mutation. Patients who have this tend to survive years long than those who do not carry the mutation. The program uses a statistical model to accurately predict the likelihood that a patient carries the IDH1 mutation and requires screening. Gliomas are often tested for IDH1 mutation following surgery to remove the tumor, but undergoing this type of testing often requires stringent insurance pre-approvals due to rising health-care costs. “Currently, there are no universally accepted guidelines for when gliomas should be tested for this mutation,” said one of the application developers. “Obtaining insurance pre-approval for additional molecular testing is becoming more commonplace, and this program will assist healthcare providers with an evidence-based rationale for when IDH1 screening is necessary.” To read more about this program, click here.